JP2004530415A - 酵素 - Google Patents

Info

Publication number

JP2004530415A

JP2004530415A JP2002548103A JP2002548103A JP2004530415A JP 2004530415 A JP2004530415 A JP 2004530415A JP 2002548103 A JP2002548103 A JP 2002548103A JP 2002548103 A JP2002548103 A JP 2002548103A JP 2004530415 A JP2004530415 A JP 2004530415A

Authority

JP

Japan

Prior art keywords

polynucleotide

polypeptide

seq

sequence

nzms

Prior art date

2000-12-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004190 Enzymes Human genes 0.000 title abstract description 52
• 108090000790 Enzymes Proteins 0.000 title abstract description 52
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 327
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 327
• 239000002157 polynucleotide Substances 0.000 claims abstract description 327
• 238000000034 method Methods 0.000 claims abstract description 194
• 230000014509 gene expression Effects 0.000 claims abstract description 119
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 79
• 201000010099 disease Diseases 0.000 claims abstract description 66
• 239000005557 antagonist Substances 0.000 claims abstract description 18
• 239000000556 agonist Substances 0.000 claims abstract description 17
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 248
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 234
• 229920001184 polypeptide Polymers 0.000 claims description 226
• 210000004027 cell Anatomy 0.000 claims description 144
• 239000012634 fragment Substances 0.000 claims description 130
• 150000001875 compounds Chemical class 0.000 claims description 124
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 112
• 150000007523 nucleic acids Chemical class 0.000 claims description 91
• 239000000523 sample Substances 0.000 claims description 89
• 125000003729 nucleotide group Chemical group 0.000 claims description 82
• 239000002773 nucleotide Substances 0.000 claims description 80
• 230000000694 effects Effects 0.000 claims description 72
• 238000009396 hybridization Methods 0.000 claims description 56
• 238000012360 testing method Methods 0.000 claims description 56
• 239000000203 mixture Substances 0.000 claims description 51
• 102000039446 nucleic acids Human genes 0.000 claims description 47
• 108020004707 nucleic acids Proteins 0.000 claims description 47
• 230000000295 complement effect Effects 0.000 claims description 39
• 230000027455 binding Effects 0.000 claims description 36
• 108091034117 Oligonucleotide Proteins 0.000 claims description 35
• 238000011282 treatment Methods 0.000 claims description 33
• 238000012216 screening Methods 0.000 claims description 31
• 239000012472 biological sample Substances 0.000 claims description 27
• 239000000758 substrate Substances 0.000 claims description 27
• 238000004519 manufacturing process Methods 0.000 claims description 25
• 230000002163 immunogen Effects 0.000 claims description 21
• 230000008569 process Effects 0.000 claims description 21
• 230000002068 genetic effect Effects 0.000 claims description 20
• 241001465754 Metazoa Species 0.000 claims description 19
• 238000002493 microarray Methods 0.000 claims description 19
• 230000001988 toxicity Effects 0.000 claims description 12
• 231100000419 toxicity Toxicity 0.000 claims description 12
• 239000007787 solid Substances 0.000 claims description 10
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
• 230000002829 reductive effect Effects 0.000 claims description 9
• 230000009870 specific binding Effects 0.000 claims description 8
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
• 238000002372 labelling Methods 0.000 claims description 5
• 108060003951 Immunoglobulin Proteins 0.000 claims description 4
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
• 210000004408 hybridoma Anatomy 0.000 claims description 4
• 102000018358 immunoglobulin Human genes 0.000 claims description 4
• 238000002156 mixing Methods 0.000 claims description 4
• 230000002018 overexpression Effects 0.000 claims description 4
• 238000012408 PCR amplification Methods 0.000 claims description 3
• 230000002596 correlated effect Effects 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 3
• 230000003053 immunization Effects 0.000 claims description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
• 230000005875 antibody response Effects 0.000 claims 2
• 210000000628 antibody-producing cell Anatomy 0.000 claims 2
• 238000002405 diagnostic procedure Methods 0.000 claims 1
• 241000282414 Homo sapiens Species 0.000 abstract description 23
• 239000013604 expression vector Substances 0.000 abstract description 22
• 230000002159 abnormal effect Effects 0.000 abstract description 9
• 108090000623 proteins and genes Proteins 0.000 description 185
• 102000004169 proteins and genes Human genes 0.000 description 119
• 235000018102 proteins Nutrition 0.000 description 110
• 239000013598 vector Substances 0.000 description 54
• 108091028043 Nucleic acid sequence Proteins 0.000 description 53
• 108010053770 Deoxyribonucleases Proteins 0.000 description 50
• 102000016911 Deoxyribonucleases Human genes 0.000 description 50
• 102000006382 Ribonucleases Human genes 0.000 description 50
• 108010083644 Ribonucleases Proteins 0.000 description 50
• 229940088598 enzyme Drugs 0.000 description 50
• 239000002299 complementary DNA Substances 0.000 description 42
• 238000002869 basic local alignment search tool Methods 0.000 description 40
• 210000001519 tissue Anatomy 0.000 description 40
• 235000001014 amino acid Nutrition 0.000 description 33
• 239000013615 primer Substances 0.000 description 32
• 102000003846 Carbonic anhydrases Human genes 0.000 description 31
• 108090000209 Carbonic anhydrases Proteins 0.000 description 30
• 150000001413 amino acids Chemical class 0.000 description 29
• 238000003752 polymerase chain reaction Methods 0.000 description 29
• 229940024606 amino acid Drugs 0.000 description 28
• 238000004458 analytical method Methods 0.000 description 27
• 239000013612 plasmid Substances 0.000 description 25
• 102000004317 Lyases Human genes 0.000 description 24
• 108090000856 Lyases Proteins 0.000 description 24
• 238000003556 assay Methods 0.000 description 22
• 230000006870 function Effects 0.000 description 21
• 238000013518 transcription Methods 0.000 description 21
• 230000035897 transcription Effects 0.000 description 21
• 238000006243 chemical reaction Methods 0.000 description 20
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
• 230000007812 deficiency Effects 0.000 description 18
• 239000003814 drug Substances 0.000 description 18
• 238000005516 engineering process Methods 0.000 description 18
• 102000004157 Hydrolases Human genes 0.000 description 16
• 108090000604 Hydrolases Proteins 0.000 description 16
• 108010026552 Proteome Proteins 0.000 description 16
• 238000004422 calculation algorithm Methods 0.000 description 16
• 238000012163 sequencing technique Methods 0.000 description 16
• 238000006467 substitution reaction Methods 0.000 description 16
• 238000006460 hydrolysis reaction Methods 0.000 description 15
• 238000000338 in vitro Methods 0.000 description 15
• 125000000539 amino acid group Chemical group 0.000 description 14
• 230000000692 anti-sense effect Effects 0.000 description 14
• 230000000875 corresponding effect Effects 0.000 description 14
• 208000019693 Lung disease Diseases 0.000 description 13
• 102000052812 Ornithine decarboxylases Human genes 0.000 description 13
• 108700005126 Ornithine decarboxylases Proteins 0.000 description 13
• 239000003153 chemical reaction reagent Substances 0.000 description 13
• 208000035475 disorder Diseases 0.000 description 13
• 230000007062 hydrolysis Effects 0.000 description 13
• 230000035772 mutation Effects 0.000 description 13
• 230000001105 regulatory effect Effects 0.000 description 13
• 230000014616 translation Effects 0.000 description 13
• 238000013519 translation Methods 0.000 description 13
• 206010028980 Neoplasm Diseases 0.000 description 12
• 230000015572 biosynthetic process Effects 0.000 description 12
• 230000004663 cell proliferation Effects 0.000 description 12
• 102100020925 Adenosylhomocysteinase Human genes 0.000 description 11
• 108091023037 Aptamer Proteins 0.000 description 11
• 108091026890 Coding region Proteins 0.000 description 11
• 241000282412 Homo Species 0.000 description 11
• 108091093037 Peptide nucleic acid Proteins 0.000 description 11
• 241000700605 Viruses Species 0.000 description 11
• 230000005856 abnormality Effects 0.000 description 11
• 230000008859 change Effects 0.000 description 11
• 238000001514 detection method Methods 0.000 description 11
• 239000003112 inhibitor Substances 0.000 description 11
• 238000000746 purification Methods 0.000 description 11
• 208000011580 syndromic disease Diseases 0.000 description 11
• 238000003786 synthesis reaction Methods 0.000 description 11
• 102000015636 Oligopeptides Human genes 0.000 description 10
• 108010038807 Oligopeptides Proteins 0.000 description 10
• 241000700584 Simplexvirus Species 0.000 description 10
• 230000001363 autoimmune Effects 0.000 description 10
• 238000003776 cleavage reaction Methods 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• 238000001415 gene therapy Methods 0.000 description 10
• 230000007017 scission Effects 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 235000000346 sugar Nutrition 0.000 description 10
• 241000124008 Mammalia Species 0.000 description 9
• 102000035195 Peptidases Human genes 0.000 description 9
• 108091005804 Peptidases Proteins 0.000 description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
• 230000001939 inductive effect Effects 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 108020004999 messenger RNA Proteins 0.000 description 9
• 238000003199 nucleic acid amplification method Methods 0.000 description 9
• -1 phosphodiester compound Chemical class 0.000 description 9
• 241000894007 species Species 0.000 description 9
• 230000002588 toxic effect Effects 0.000 description 9
• 241000701161 unidentified adenovirus Species 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• 108020002202 Adenosylhomocysteinase Proteins 0.000 description 8
• 208000023275 Autoimmune disease Diseases 0.000 description 8
• 102000053602 DNA Human genes 0.000 description 8
• 241000196324 Embryophyta Species 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 208000012902 Nervous system disease Diseases 0.000 description 8
• 102000005262 Sulfatase Human genes 0.000 description 8
• 230000003321 amplification Effects 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 210000001124 body fluid Anatomy 0.000 description 8
• 239000010839 body fluid Substances 0.000 description 8
• 201000011510 cancer Diseases 0.000 description 8
• 230000002759 chromosomal effect Effects 0.000 description 8
• 210000000349 chromosome Anatomy 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• 210000000688 human artificial chromosome Anatomy 0.000 description 8
• 238000001727 in vivo Methods 0.000 description 8
• 210000004379 membrane Anatomy 0.000 description 8
• 239000012528 membrane Substances 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 230000002685 pulmonary effect Effects 0.000 description 8
• 238000002864 sequence alignment Methods 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 108060007951 sulfatase Proteins 0.000 description 8
• 231100000331 toxic Toxicity 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 108090000994 Catalytic RNA Proteins 0.000 description 7
• 102000053642 Catalytic RNA Human genes 0.000 description 7
• 108020004705 Codon Proteins 0.000 description 7
• 238000001712 DNA sequencing Methods 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 7
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 238000010367 cloning Methods 0.000 description 7
• 238000012217 deletion Methods 0.000 description 7
• 230000037430 deletion Effects 0.000 description 7
• 238000003745 diagnosis Methods 0.000 description 7
• 239000003623 enhancer Substances 0.000 description 7
• 230000002255 enzymatic effect Effects 0.000 description 7
• 230000028993 immune response Effects 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• 208000027866 inflammatory disease Diseases 0.000 description 7
• 210000004185 liver Anatomy 0.000 description 7
• 230000010076 replication Effects 0.000 description 7
• 108091092562 ribozyme Proteins 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• 230000009466 transformation Effects 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• 208000030507 AIDS Diseases 0.000 description 6
• 201000001320 Atherosclerosis Diseases 0.000 description 6
• 208000024172 Cardiovascular disease Diseases 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 108700024394 Exon Proteins 0.000 description 6
• 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 6
• 208000018522 Gastrointestinal disease Diseases 0.000 description 6
• 206010020751 Hypersensitivity Diseases 0.000 description 6
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 6
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 6
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
• 238000000137 annealing Methods 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 210000004556 brain Anatomy 0.000 description 6
• 150000001720 carbohydrates Chemical class 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 238000003018 immunoassay Methods 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 235000019833 protease Nutrition 0.000 description 6
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 6
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
• 241001430294 unidentified retrovirus Species 0.000 description 6
• 241000283690 Bos taurus Species 0.000 description 5
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
• 108020004635 Complementary DNA Proteins 0.000 description 5
• 206010010356 Congenital anomaly Diseases 0.000 description 5
• 108091035707 Consensus sequence Proteins 0.000 description 5
• 108010042407 Endonucleases Proteins 0.000 description 5
• 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 5
• 101000716952 Homo sapiens Adenosylhomocysteinase Proteins 0.000 description 5
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
• 239000004472 Lysine Substances 0.000 description 5
• 108020002496 Lysophospholipase Proteins 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 229910019142 PO4 Inorganic materials 0.000 description 5
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 208000026935 allergic disease Diseases 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 239000000427 antigen Substances 0.000 description 5
• 230000000890 antigenic effect Effects 0.000 description 5
• 108091007433 antigens Proteins 0.000 description 5
• 102000036639 antigens Human genes 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 238000001574 biopsy Methods 0.000 description 5
• 235000014633 carbohydrates Nutrition 0.000 description 5
• 229910002092 carbon dioxide Inorganic materials 0.000 description 5
• 230000001086 cytosolic effect Effects 0.000 description 5
• 208000030533 eye disease Diseases 0.000 description 5
• 239000007850 fluorescent dye Substances 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• 208000006454 hepatitis Diseases 0.000 description 5
• 231100000283 hepatitis Toxicity 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 210000000496 pancreas Anatomy 0.000 description 5
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
• 239000010452 phosphate Substances 0.000 description 5
• 102000054765 polymorphisms of proteins Human genes 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 239000002987 primer (paints) Substances 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 150000003384 small molecules Chemical class 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 230000032258 transport Effects 0.000 description 5
• 241001529453 unidentified herpesvirus Species 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
• 230000005730 ADP ribosylation Effects 0.000 description 4
• 102000009836 Aconitate hydratase Human genes 0.000 description 4
• 108010009924 Aconitate hydratase Proteins 0.000 description 4
• 102000055025 Adenosine deaminases Human genes 0.000 description 4
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
• 241000710929 Alphavirus Species 0.000 description 4
• 102000004031 Carboxy-Lyases Human genes 0.000 description 4
• 108090000489 Carboxy-Lyases Proteins 0.000 description 4
• 102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 4
• 108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 4
• 206010014561 Emphysema Diseases 0.000 description 4
• 102000004533 Endonucleases Human genes 0.000 description 4
• 108060002716 Exonuclease Proteins 0.000 description 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
• 101710154606 Hemagglutinin Proteins 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 108010044467 Isoenzymes Proteins 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• 208000025966 Neurological disease Diseases 0.000 description 4
• 108700026244 Open Reading Frames Proteins 0.000 description 4
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
• 101710176177 Protein A56 Proteins 0.000 description 4
• 229930185560 Pseudouridine Natural products 0.000 description 4
• PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 206010037394 Pulmonary haemorrhage Diseases 0.000 description 4
• 108091028664 Ribonucleotide Proteins 0.000 description 4
• 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 4
• 241000714474 Rous sarcoma virus Species 0.000 description 4
• 238000012300 Sequence Analysis Methods 0.000 description 4
• 108091081024 Start codon Proteins 0.000 description 4
• 241000282887 Suidae Species 0.000 description 4
• 102000005488 Thioesterase Human genes 0.000 description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
• 241000700618 Vaccinia virus Species 0.000 description 4
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
• 208000036142 Viral infection Diseases 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 206010006451 bronchitis Diseases 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
• 239000000470 constituent Substances 0.000 description 4
• 238000010276 construction Methods 0.000 description 4
• 238000006114 decarboxylation reaction Methods 0.000 description 4
• 238000007877 drug screening Methods 0.000 description 4
• 102000013165 exonuclease Human genes 0.000 description 4
• 238000010353 genetic engineering Methods 0.000 description 4
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
• 239000000185 hemagglutinin Substances 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 230000000968 intestinal effect Effects 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 206010028417 myasthenia gravis Diseases 0.000 description 4
• 238000004806 packaging method and process Methods 0.000 description 4
• 208000005987 polymyositis Diseases 0.000 description 4
• 210000002307 prostate Anatomy 0.000 description 4
• PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 4
• 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 4
• 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 4
• 229960001327 pyridoxal phosphate Drugs 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 230000001177 retroviral effect Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 239000002336 ribonucleotide Substances 0.000 description 4
• 125000002652 ribonucleotide group Chemical group 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 150000008163 sugars Chemical class 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
• 108020002982 thioesterase Proteins 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• 238000002054 transplantation Methods 0.000 description 4
• 210000003932 urinary bladder Anatomy 0.000 description 4
• 230000009385 viral infection Effects 0.000 description 4
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
• 108091006112 ATPases Proteins 0.000 description 3
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
• 208000000044 Amnesia Diseases 0.000 description 3
• 208000031091 Amnestic disease Diseases 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 241000972773 Aulopiformes Species 0.000 description 3
• 208000023328 Basedow disease Diseases 0.000 description 3
• 206010006448 Bronchiolitis Diseases 0.000 description 3
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
• 102100024650 Carbonic anhydrase 3 Human genes 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• 239000003155 DNA primer Substances 0.000 description 3
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 108700034774 EC 4.99.-.- Proteins 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• 201000011240 Frontotemporal dementia Diseases 0.000 description 3
• 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 3
• 206010017533 Fungal infection Diseases 0.000 description 3
• 241000233866 Fungi Species 0.000 description 3
• 208000010412 Glaucoma Diseases 0.000 description 3
• 108091022930 Glutamate decarboxylase Proteins 0.000 description 3
• 102000008214 Glutamate decarboxylase Human genes 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 208000024869 Goodpasture syndrome Diseases 0.000 description 3
• 208000015023 Graves' disease Diseases 0.000 description 3
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 3
• 108010014095 Histidine decarboxylase Proteins 0.000 description 3
• 102100037095 Histidine decarboxylase Human genes 0.000 description 3
• 101000760630 Homo sapiens Carbonic anhydrase 3 Proteins 0.000 description 3
• 206010061598 Immunodeficiency Diseases 0.000 description 3
• 208000029462 Immunodeficiency disease Diseases 0.000 description 3
• 102100034349 Integrase Human genes 0.000 description 3
• 108020003285 Isocitrate lyase Proteins 0.000 description 3
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• 102000003960 Ligases Human genes 0.000 description 3
• 108090000364 Ligases Proteins 0.000 description 3
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
• 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 3
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 3
• 208000031888 Mycoses Diseases 0.000 description 3
• 101710163270 Nuclease Proteins 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 206010033645 Pancreatitis Diseases 0.000 description 3
• 208000018737 Parkinson disease Diseases 0.000 description 3
• 206010035664 Pneumonia Diseases 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 239000005700 Putrescine Substances 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 201000009594 Systemic Scleroderma Diseases 0.000 description 3
• 206010042953 Systemic sclerosis Diseases 0.000 description 3
• 102100036407 Thioredoxin Human genes 0.000 description 3
• 108020004440 Thymidine kinase Proteins 0.000 description 3
• 229960005305 adenosine Drugs 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 230000006986 amnesia Effects 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 208000011775 arteriosclerosis disease Diseases 0.000 description 3
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000002459 blastocyst Anatomy 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 150000001768 cations Chemical class 0.000 description 3
• 230000010261 cell growth Effects 0.000 description 3
• 208000026106 cerebrovascular disease Diseases 0.000 description 3
• 201000001352 cholecystitis Diseases 0.000 description 3
• 230000004087 circulation Effects 0.000 description 3
• 230000007882 cirrhosis Effects 0.000 description 3
• 208000019425 cirrhosis of liver Diseases 0.000 description 3
• 238000012875 competitive assay Methods 0.000 description 3
• 239000003184 complementary RNA Substances 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 201000001981 dermatomyositis Diseases 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 201000006549 dyspepsia Diseases 0.000 description 3
• 230000002124 endocrine Effects 0.000 description 3
• 206010015037 epilepsy Diseases 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 230000004110 gluconeogenesis Effects 0.000 description 3
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 208000019622 heart disease Diseases 0.000 description 3
• 238000002744 homologous recombination Methods 0.000 description 3
• 230000006801 homologous recombination Effects 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000007813 immunodeficiency Effects 0.000 description 3
• 230000016784 immunoglobulin production Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 208000014674 injury Diseases 0.000 description 3
• 208000002551 irritable bowel syndrome Diseases 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 238000013507 mapping Methods 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 244000045947 parasite Species 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 230000000737 periodic effect Effects 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 229920000768 polyamine Polymers 0.000 description 3
• 230000000644 propagated effect Effects 0.000 description 3
• 201000009732 pulmonary eosinophilia Diseases 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 208000017443 reproductive system disease Diseases 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 108091008146 restriction endonucleases Proteins 0.000 description 3
• 210000003079 salivary gland Anatomy 0.000 description 3
• 235000019515 salmon Nutrition 0.000 description 3
• 201000000980 schizophrenia Diseases 0.000 description 3
• 208000012672 seasonal affective disease Diseases 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 230000021595 spermatogenesis Effects 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 210000001550 testis Anatomy 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 108060008226 thioredoxin Proteins 0.000 description 3
• 206010043554 thrombocytopenia Diseases 0.000 description 3
• 201000005060 thrombophlebitis Diseases 0.000 description 3
• 229940113082 thymine Drugs 0.000 description 3
• 210000001541 thymus gland Anatomy 0.000 description 3
• 238000010361 transduction Methods 0.000 description 3
• 230000026683 transduction Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• UQIHHGNTYLFRNX-ALKRTJFJSA-N (2s)-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-2-(2-hydroxypropanoylamino)-5-oxopentanoic acid Chemical compound CC(O)C(=O)N[C@H](C(O)=O)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O UQIHHGNTYLFRNX-ALKRTJFJSA-N 0.000 description 2
• ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
• 108091000044 4-hydroxy-tetrahydrodipicolinate synthase Proteins 0.000 description 2
• SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 2
• 102000011932 ATPases Associated with Diverse Cellular Activities Human genes 0.000 description 2
• 108010075752 ATPases Associated with Diverse Cellular Activities Proteins 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 206010001881 Alveolar proteinosis Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 206010002198 Anaphylactic reaction Diseases 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 2
• 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 2
• 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 2
• 102100031491 Arylsulfatase B Human genes 0.000 description 2
• 108700016171 Aspartate ammonia-lyases Proteins 0.000 description 2
• 206010068220 Aspartylglucosaminuria Diseases 0.000 description 2
• 206010003591 Ataxia Diseases 0.000 description 2
• 208000004300 Atrophic Gastritis Diseases 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000012219 Autonomic Nervous System disease Diseases 0.000 description 2
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 2
• 208000035143 Bacterial infection Diseases 0.000 description 2
• 231100000699 Bacterial toxin Toxicity 0.000 description 2
• 208000004020 Brain Abscess Diseases 0.000 description 2
• 206010006458 Bronchitis chronic Diseases 0.000 description 2
• 206010006811 Bursitis Diseases 0.000 description 2
• YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
• 102000000584 Calmodulin Human genes 0.000 description 2
• 108010041952 Calmodulin Proteins 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 108090000565 Capsid Proteins Proteins 0.000 description 2
• 102100024644 Carbonic anhydrase 4 Human genes 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 102100023321 Ceruloplasmin Human genes 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 208000029147 Collagen-vascular disease Diseases 0.000 description 2
• 206010010099 Combined immunodeficiency Diseases 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 108020004394 Complementary RNA Proteins 0.000 description 2
• 208000019736 Cranial nerve disease Diseases 0.000 description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
• 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
• 108010017826 DNA Polymerase I Proteins 0.000 description 2
• 102000004594 DNA Polymerase I Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• 208000012239 Developmental disease Diseases 0.000 description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 201000010374 Down Syndrome Diseases 0.000 description 2
• 208000014094 Dystonic disease Diseases 0.000 description 2
• 201000009273 Endometriosis Diseases 0.000 description 2
• 241001635598 Enicostema Species 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 206010015226 Erythema nodosum Diseases 0.000 description 2
• 206010049466 Erythroblastosis Diseases 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• 206010061846 Extradural abscess Diseases 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 229930091371 Fructose Natural products 0.000 description 2
• 239000005715 Fructose Substances 0.000 description 2
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
• 108010036781 Fumarate Hydratase Proteins 0.000 description 2
• 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 description 2
• 108091006027 G proteins Proteins 0.000 description 2
• 102000030782 GTP binding Human genes 0.000 description 2
• 108091000058 GTP-Binding Proteins 0.000 description 2
• 208000003098 Ganglion Cysts Diseases 0.000 description 2
• 208000036495 Gastritis atrophic Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920002683 Glycosaminoglycan Polymers 0.000 description 2
• 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
• 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
• 201000005569 Gout Diseases 0.000 description 2
• 208000006968 Helminthiasis Diseases 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000760567 Homo sapiens Carbonic anhydrase 4 Proteins 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 101710203526 Integrase Proteins 0.000 description 2
• 208000029523 Interstitial Lung disease Diseases 0.000 description 2
• AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
• 108090001060 Lipase Proteins 0.000 description 2
• 102000004882 Lipase Human genes 0.000 description 2
• 239000004367 Lipase Substances 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 206010025327 Lymphopenia Diseases 0.000 description 2
• 208000015439 Lysosomal storage disease Diseases 0.000 description 2
• 206010027202 Meningitis bacterial Diseases 0.000 description 2
• 206010027260 Meningitis viral Diseases 0.000 description 2
• 208000036626 Mental retardation Diseases 0.000 description 2
• 206010068836 Metabolic myopathy Diseases 0.000 description 2
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
• AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
• 208000001572 Mycoplasma Pneumonia Diseases 0.000 description 2
• 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 2
• 208000003926 Myelitis Diseases 0.000 description 2
• 206010028643 Myopathy endocrine Diseases 0.000 description 2
• 206010028648 Myopathy toxic Diseases 0.000 description 2
• 208000023137 Myotoxicity Diseases 0.000 description 2
• 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 2
• CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
• BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 108010071195 Nucleotidases Proteins 0.000 description 2
• 102000007533 Nucleotidases Human genes 0.000 description 2
• 208000011623 Obstructive Lung disease Diseases 0.000 description 2
• 208000022873 Ocular disease Diseases 0.000 description 2
• 206010030043 Ocular hypertension Diseases 0.000 description 2
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 208000030852 Parasitic disease Diseases 0.000 description 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 206010035610 Pleural Neoplasms Diseases 0.000 description 2
• 208000002151 Pleural effusion Diseases 0.000 description 2
• 206010035737 Pneumonia viral Diseases 0.000 description 2
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 208000024777 Prion disease Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 208000001431 Psychomotor Agitation Diseases 0.000 description 2
• 208000010378 Pulmonary Embolism Diseases 0.000 description 2
• 206010037368 Pulmonary congestion Diseases 0.000 description 2
• 208000006193 Pulmonary infarction Diseases 0.000 description 2
• 206010037423 Pulmonary oedema Diseases 0.000 description 2
• RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
• 108091034057 RNA (poly(A)) Proteins 0.000 description 2
• 108020004518 RNA Probes Proteins 0.000 description 2
• 239000003391 RNA probe Substances 0.000 description 2
• 206010037779 Radiculopathy Diseases 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 206010038743 Restlessness Diseases 0.000 description 2
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
• ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 241000710960 Sindbis virus Species 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 2
• 208000029033 Spinal Cord disease Diseases 0.000 description 2
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
• 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 108091027544 Subgenomic mRNA Proteins 0.000 description 2
• 208000005400 Synovial Cyst Diseases 0.000 description 2
• 108091036066 Three prime untranslated region Proteins 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 102000009843 Thyroglobulin Human genes 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 208000000323 Tourette Syndrome Diseases 0.000 description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
• 108020004566 Transfer RNA Proteins 0.000 description 2
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
• 108010035075 Tyrosine decarboxylase Proteins 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 108091023045 Untranslated Region Proteins 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 201000011032 Werner Syndrome Diseases 0.000 description 2
• PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 2
• 208000017733 acquired polycythemia vera Diseases 0.000 description 2
• 208000009621 actinic keratosis Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 150000001409 amidines Chemical class 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 238000002399 angioplasty Methods 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 239000000074 antisense oligonucleotide Substances 0.000 description 2
• 238000012230 antisense oligonucleotides Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 208000022362 bacterial infectious disease Diseases 0.000 description 2
• 201000009904 bacterial meningitis Diseases 0.000 description 2
• 239000000688 bacterial toxin Substances 0.000 description 2
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000008236 biological pathway Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 210000000625 blastula Anatomy 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 201000009267 bronchiectasis Diseases 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000001569 carbon dioxide Substances 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 206010007776 catatonia Diseases 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000033077 cellular process Effects 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 229940106189 ceramide Drugs 0.000 description 2
• ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 206010008129 cerebral palsy Diseases 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
• 208000007451 chronic bronchitis Diseases 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 230000009918 complex formation Effects 0.000 description 2
• 238000004590 computer program Methods 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 239000005547 deoxyribonucleotide Substances 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
• 208000010118 dystonia Diseases 0.000 description 2
• 239000003792 electrolyte Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 206010014665 endocarditis Diseases 0.000 description 2
• 230000002616 endonucleolytic effect Effects 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 201000000165 epidural abscess Diseases 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• 230000002964 excitative effect Effects 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 210000000232 gallbladder Anatomy 0.000 description 2
• 150000002270 gangliosides Chemical class 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 238000001476 gene delivery Methods 0.000 description 2
• 102000054767 gene variant Human genes 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 229930182470 glycoside Natural products 0.000 description 2
• 150000002338 glycosides Chemical class 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
• 238000001631 haemodialysis Methods 0.000 description 2
• 230000000322 hemodialysis Effects 0.000 description 2
• 201000003636 hereditary ataxia Diseases 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000003301 hydrolyzing effect Effects 0.000 description 2
• 230000009610 hypersensitivity Effects 0.000 description 2
• 230000036737 immune function Effects 0.000 description 2
• 238000007901 in situ hybridization Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 230000031146 intracellular signal transduction Effects 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 2
• DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
• 206010023497 kuru Diseases 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 235000019421 lipase Nutrition 0.000 description 2
• 230000037356 lipid metabolism Effects 0.000 description 2
• 230000029226 lipidation Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 230000005823 lung abnormality Effects 0.000 description 2
• 201000003453 lung abscess Diseases 0.000 description 2
• 230000005980 lung dysfunction Effects 0.000 description 2
• 208000020816 lung neoplasm Diseases 0.000 description 2
• 208000037841 lung tumor Diseases 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 231100001023 lymphopenia Toxicity 0.000 description 2
• 230000002132 lysosomal effect Effects 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 230000005291 magnetic effect Effects 0.000 description 2
• 239000006249 magnetic particle Substances 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 230000037353 metabolic pathway Effects 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 229960004452 methionine Drugs 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
• 230000002438 mitochondrial effect Effects 0.000 description 2
• 238000000329 molecular dynamics simulation Methods 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 206010028537 myelofibrosis Diseases 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• 229930014626 natural product Natural products 0.000 description 2
• 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 230000002232 neuromuscular Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 229920001542 oligosaccharide Polymers 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 229960003104 ornithine Drugs 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 2
• 230000000849 parathyroid Effects 0.000 description 2
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 210000003899 penis Anatomy 0.000 description 2
• 229940111202 pepsin Drugs 0.000 description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 description 2
• 210000002824 peroxisome Anatomy 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
• 229950004354 phosphorylcholine Drugs 0.000 description 2
• PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 2
• 201000003437 pleural cancer Diseases 0.000 description 2
• 206010035653 pneumoconiosis Diseases 0.000 description 2
• 201000003144 pneumothorax Diseases 0.000 description 2
• 208000037244 polycythemia vera Diseases 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000006337 proteolytic cleavage Effects 0.000 description 2
• 108010049718 pseudouridine synthases Proteins 0.000 description 2
• 208000020016 psychiatric disease Diseases 0.000 description 2
• 208000005333 pulmonary edema Diseases 0.000 description 2
• 208000002815 pulmonary hypertension Diseases 0.000 description 2
• 230000007575 pulmonary infarction Effects 0.000 description 2
• 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 206010061928 radiculitis Diseases 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
• PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 108010058198 sulfoalanine decarboxylase Proteins 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 229960003080 taurine Drugs 0.000 description 2
• 208000001608 teratocarcinoma Diseases 0.000 description 2
• 229960002175 thyroglobulin Drugs 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 230000008791 toxic response Effects 0.000 description 2
• 230000002110 toxicologic effect Effects 0.000 description 2
• 231100000027 toxicology Toxicity 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
• 208000009999 tuberous sclerosis Diseases 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 229940035893 uracil Drugs 0.000 description 2
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
• 229940045145 uridine Drugs 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 201000010044 viral meningitis Diseases 0.000 description 2
• 208000009421 viral pneumonia Diseases 0.000 description 2
• RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• UWOCFOFVIBZJGH-UHFFFAOYSA-N 2,3-dihydrodipicolinic acid Chemical compound OC(=O)C1CC=CC(C(O)=O)=N1 UWOCFOFVIBZJGH-UHFFFAOYSA-N 0.000 description 1
• OWEFQTXQEHYDEJ-UHFFFAOYSA-N 2,3-dihydroxypropanal diphosphono hydrogen phosphate Chemical compound OCC(O)C=O.OP(O)(=O)OP(O)(=O)OP(O)(O)=O OWEFQTXQEHYDEJ-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 1
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• 102100022464 5'-nucleotidase Human genes 0.000 description 1
• LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
• 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• 102000009067 AAA Proteins Human genes 0.000 description 1
• 108010087671 AAA Proteins Proteins 0.000 description 1
• PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
• 102000020236 ADP-ribosylarginine hydrolase Human genes 0.000 description 1
• 108010079768 ADP-ribosylarginine hydrolase Proteins 0.000 description 1
• 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
• 102100034213 ATPase family protein 2 homolog Human genes 0.000 description 1
• 102100033639 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 208000010444 Acidosis Diseases 0.000 description 1
• 102100040958 Aconitate hydratase, mitochondrial Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108700016155 Acyl transferases Proteins 0.000 description 1
• 102000057234 Acyl transferases Human genes 0.000 description 1
• 101710120269 Acyl-CoA thioester hydrolase YbgC Proteins 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 229930024421 Adenine Natural products 0.000 description 1
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 102000009346 Adenosine receptors Human genes 0.000 description 1
• 108050000203 Adenosine receptors Proteins 0.000 description 1
• 102000005234 Adenosylhomocysteinase Human genes 0.000 description 1
• 206010001367 Adrenal insufficiency Diseases 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• 108090000072 Aldehyde-Lyases Proteins 0.000 description 1
• 102000003677 Aldehyde-Lyases Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 101710191958 Amino-acid acetyltransferase Proteins 0.000 description 1
• 102000014161 Aminohydrolases Human genes 0.000 description 1
• 108010011527 Aminohydrolases Proteins 0.000 description 1
• 108090000673 Ammonia-Lyases Proteins 0.000 description 1
• 102000004118 Ammonia-Lyases Human genes 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 102100022987 Angiogenin Human genes 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 102100023167 Argininosuccinate lyase Human genes 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 206010003226 Arteriovenous fistula Diseases 0.000 description 1
• 102100023943 Arylsulfatase L Human genes 0.000 description 1
• 101710115246 Arylsulfatase L Proteins 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical compound OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010004552 Bicuspid aortic valve Diseases 0.000 description 1
• 208000015163 Biliary Tract disease Diseases 0.000 description 1
• 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 101710115432 Brain ribonuclease Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 241000244203 Caenorhabditis elegans Species 0.000 description 1
• 101100152433 Caenorhabditis elegans tat-1 gene Proteins 0.000 description 1
• 102000007590 Calpain Human genes 0.000 description 1
• 108010032088 Calpain Proteins 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 108010051152 Carboxylesterase Proteins 0.000 description 1
• 102000013392 Carboxylesterase Human genes 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 102000005600 Cathepsins Human genes 0.000 description 1
• 108010084457 Cathepsins Proteins 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 208000014912 Central Nervous System Infections Diseases 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 239000005496 Chlorsulfuron Substances 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 206010008635 Cholestasis Diseases 0.000 description 1
• 241000511343 Chondrostoma nasus Species 0.000 description 1
• 108090000746 Chymosin Proteins 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 102100022641 Coagulation factor IX Human genes 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 241000272201 Columbiformes Species 0.000 description 1
• 208000002330 Congenital Heart Defects Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000938605 Crocodylia Species 0.000 description 1
• 241000192700 Cyanobacteria Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• 229930182843 D-Lactic acid Natural products 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
• LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
• ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 description 1
• ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 108010035533 Drosophila Proteins Proteins 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 201000004315 EAST syndrome Diseases 0.000 description 1
• 108700035100 EC 4.2.1.52 Proteins 0.000 description 1
• UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 1
• 206010062608 Endocarditis noninfective Diseases 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 241000701867 Enterobacteria phage T7 Species 0.000 description 1
• 101000940337 Enterococcus faecalis (strain EnGen0310 / MMH594) L-tyrosine decarboxylase Proteins 0.000 description 1
• 206010058838 Enterocolitis infectious Diseases 0.000 description 1
• 101710091045 Envelope protein Proteins 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 208000007217 Esophageal Stenosis Diseases 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 108091060211 Expressed sequence tag Proteins 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 208000026351 Fallopian Tube disease Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 241000230562 Flavobacteriia Species 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 208000009796 Gangliosidoses Diseases 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
• 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
• 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
• 108010060309 Glucuronidase Proteins 0.000 description 1
• 102000053187 Glucuronidase Human genes 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 229930189936 Glyoxalase Natural products 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 208000035185 Hemolytic Congenital Anemia Diseases 0.000 description 1
• 208000031220 Hemophilia Diseases 0.000 description 1
• 208000009292 Hemophilia A Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 206010058991 Hepatic vein occlusion Diseases 0.000 description 1
• 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 206010019860 Hereditary angioedema Diseases 0.000 description 1
• 206010060893 Hereditary haemolytic anaemia Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101000965314 Homo sapiens Aconitate hydratase, mitochondrial Proteins 0.000 description 1
• 101000923070 Homo sapiens Arylsulfatase B Proteins 0.000 description 1
• 101000984236 Homo sapiens Carbonic anhydrase 1 Proteins 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
• 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
• 102000004867 Hydro-Lyases Human genes 0.000 description 1
• 108090001042 Hydro-Lyases Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
• 108700022128 Hypermethioninemia Proteins 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 101150027427 ICP4 gene Proteins 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 206010021518 Impaired gastric emptying Diseases 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 206010022678 Intestinal infections Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• 208000007976 Ketosis Diseases 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 125000000635 L-ornithyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 101710096582 L-tyrosine decarboxylase Proteins 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 108010059801 Lactase-Phlorizin Hydrolase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010062062 Large intestinal obstruction Diseases 0.000 description 1
• 108700005090 Lethal Genes Proteins 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000024369 Libman-Sacks endocarditis Diseases 0.000 description 1
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
• 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
• 208000033868 Lysosomal disease Diseases 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 206010026712 Mallory-Weiss syndrome Diseases 0.000 description 1
• 241000940612 Medina Species 0.000 description 1
• 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 102000016397 Methyltransferase Human genes 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 1
• 208000025923 Mucopolysaccharidosis type 4B Diseases 0.000 description 1
• 108700005084 Multigene Family Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100042676 Mus musculus Skap2 gene Proteins 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 241000244206 Nematoda Species 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010056528 Neonatal cholestasis Diseases 0.000 description 1
• 241001028048 Nicola Species 0.000 description 1
• 208000014060 Niemann-Pick disease Diseases 0.000 description 1
• 102100034217 Non-secretory ribonuclease Human genes 0.000 description 1
• 101710118518 Non-secretory ribonuclease Proteins 0.000 description 1
• 108091005461 Nucleic proteins Chemical group 0.000 description 1
• 101150100692 ODC gene Proteins 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 206010030184 Oesophageal spasm Diseases 0.000 description 1
• 206010030194 Oesophageal stenosis Diseases 0.000 description 1
• 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 206010067472 Organising pneumonia Diseases 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 208000005345 Osteopetrosis with renal tubular acidosis Diseases 0.000 description 1
• 108700000193 Osteopetrosis with renal tubular acidosis Proteins 0.000 description 1
• 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 108090000417 Oxygenases Proteins 0.000 description 1
• 102000004020 Oxygenases Human genes 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 101150089367 PRUNE1 gene Proteins 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000004362 Penile Induration Diseases 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 208000020758 Peyronie disease Diseases 0.000 description 1
• 102100040402 Phlorizin hydrolase Human genes 0.000 description 1
• 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
• 102000004035 Phosphoenolpyruvate carboxykinase (ATP) Human genes 0.000 description 1
• 108050008598 Phosphoesterases Proteins 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
• 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
• 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 241000881705 Porcine endogenous retrovirus Species 0.000 description 1
• 208000006994 Precancerous Conditions Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 206010036783 Proctitis ulcerative Diseases 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 208000012287 Prolapse Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 206010037075 Protozoal infections Diseases 0.000 description 1
• 208000010362 Protozoan Infections Diseases 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 206010037651 Pyometra Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 108050004379 Pyrimidine 5-nucleotidases Proteins 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 108091008103 RNA aptamers Proteins 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 101000876804 Rattus norvegicus Liver carboxylesterase B-1 Proteins 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 102100028255 Renin Human genes 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 201000007981 Reye syndrome Diseases 0.000 description 1
• 102100026386 Ribonuclease K6 Human genes 0.000 description 1
• 108090000621 Ribonuclease P Proteins 0.000 description 1
• 102000004167 Ribonuclease P Human genes 0.000 description 1
• 102000004389 Ribonucleoproteins Human genes 0.000 description 1
• 108010081734 Ribonucleoproteins Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000235343 Saccharomycetales Species 0.000 description 1
• 241000288961 Saguinus imperator Species 0.000 description 1
• 241000288960 Saguinus oedipus Species 0.000 description 1
• 241000235346 Schizosaccharomyces Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 239000012506 Sephacryl® Substances 0.000 description 1
• 208000036623 Severe mental retardation Diseases 0.000 description 1
• 101710150766 Sialic acid-binding lectin Proteins 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 102000039471 Small Nuclear RNA Human genes 0.000 description 1
• 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
• 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 244000061458 Solanum melongena Species 0.000 description 1
• 235000002597 Solanum melongena Nutrition 0.000 description 1
• 108091027076 Spiegelmer Proteins 0.000 description 1
• 208000000277 Splenic Neoplasms Diseases 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 102100027918 Sucrase-isomaltase, intestinal Human genes 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 206010048327 Supranuclear palsy Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 108010006785 Taq Polymerase Proteins 0.000 description 1
• 208000031320 Teratogenesis Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 208000002903 Thalassemia Diseases 0.000 description 1
• 108010082788 Thiolester Hydrolases Proteins 0.000 description 1
• 102000004126 Thiolester Hydrolases Human genes 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 108010034949 Thyroglobulin Proteins 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 108010064762 Uroporphyrinogen decarboxylase Proteins 0.000 description 1
• 102000015437 Uroporphyrinogen decarboxylase Human genes 0.000 description 1
• 206010046798 Uterine leiomyoma Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010046996 Varicose vein Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010058990 Venous occlusion Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
• 208000027207 Whipple disease Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
• 229960000571 acetazolamide Drugs 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000007950 acidosis Effects 0.000 description 1
• 208000026545 acidosis disease Diseases 0.000 description 1
• 229940091179 aconitate Drugs 0.000 description 1
• GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 101150027964 ada gene Proteins 0.000 description 1
• 229960000643 adenine Drugs 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 210000003486 adipose tissue brown Anatomy 0.000 description 1
• 210000000593 adipose tissue white Anatomy 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 238000011256 aggressive treatment Methods 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
• 238000005882 aldol condensation reaction Methods 0.000 description 1
• 150000001323 aldoses Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
• 108010028144 alpha-Glucosidases Proteins 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 108010072788 angiogenin Proteins 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 239000004410 anthocyanin Substances 0.000 description 1
• 229930002877 anthocyanin Natural products 0.000 description 1
• 235000010208 anthocyanin Nutrition 0.000 description 1
• 150000004636 anthocyanins Chemical class 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940125644 antibody drug Drugs 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 206010002906 aortic stenosis Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 210000001742 aqueous humor Anatomy 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 201000003294 autosomal recessive osteopetrosis 3 Diseases 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 208000018300 basal ganglia disease Diseases 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 208000021654 bicuspid aortic valve disease Diseases 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
• 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 208000011803 breast fibrocystic disease Diseases 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000021523 carboxylation Effects 0.000 description 1
• 238000006473 carboxylation reaction Methods 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 208000005761 carcinoid heart disease Diseases 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 210000002421 cell wall Anatomy 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 229920001429 chelating resin Polymers 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 239000005081 chemiluminescent agent Substances 0.000 description 1
• 230000001767 chemoprotection Effects 0.000 description 1
• VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
• 201000001883 cholelithiasis Diseases 0.000 description 1
• 230000007870 cholestasis Effects 0.000 description 1
• 231100000359 cholestasis Toxicity 0.000 description 1
• 208000001020 chondrodysplasia punctata Diseases 0.000 description 1
• 210000002987 choroid plexus Anatomy 0.000 description 1
• 238000003200 chromosome mapping Methods 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229940080701 chymosin Drugs 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 210000002777 columnar cell Anatomy 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 201000001516 congenital hemolytic anemia Diseases 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000009402 cross-breeding Methods 0.000 description 1
• 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
• 201000008230 cutaneous porphyria Diseases 0.000 description 1
• 150000003950 cyclic amides Chemical class 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 229940022769 d- lactic acid Drugs 0.000 description 1
• 102100032354 dTDP-D-glucose 4,6-dehydratase Human genes 0.000 description 1
• 101710115238 dTDP-D-glucose 4,6-dehydratase Proteins 0.000 description 1
• YSYKRGRSMLTJNL-URARBOGNSA-N dTDP-alpha-D-glucose Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)C1 YSYKRGRSMLTJNL-URARBOGNSA-N 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 239000003398 denaturant Substances 0.000 description 1
• 238000001784 detoxification Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• RBNPZEHAODHBPZ-UHFFFAOYSA-M dihydroxyaluminium Chemical compound O.O.NCC(=O)O[Al] RBNPZEHAODHBPZ-UHFFFAOYSA-M 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 208000022837 disorder of methionine catabolism Diseases 0.000 description 1
• 238000002224 dissection Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000007878 drug screening assay Methods 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 241001233061 earthworms Species 0.000 description 1
• UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 1
• 208000002296 eclampsia Diseases 0.000 description 1
• 210000001705 ectoderm cell Anatomy 0.000 description 1
• 201000003511 ectopic pregnancy Diseases 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000004039 endoderm cell Anatomy 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000005183 environmental health Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 201000006517 essential tremor Diseases 0.000 description 1
• 230000012173 estrus Effects 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000010429 evolutionary process Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000001263 extrapyramidal tract Anatomy 0.000 description 1
• 230000001815 facial effect Effects 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 208000024987 familial hemolytic anemia Diseases 0.000 description 1
• 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
• 201000006061 fatal familial insomnia Diseases 0.000 description 1
• 230000004129 fatty acid metabolism Effects 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 238000010304 firing Methods 0.000 description 1
• 230000009969 flowable effect Effects 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 235000021588 free fatty acids Nutrition 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
• 208000001288 gastroparesis Diseases 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 208000037824 growth disorder Diseases 0.000 description 1
• 201000000079 gynecomastia Diseases 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 150000002366 halogen compounds Chemical class 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000024798 heartburn Diseases 0.000 description 1
• 208000031169 hemorrhagic disease Diseases 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000007386 hepatic encephalopathy Diseases 0.000 description 1
• 206010019680 hepatic infarction Diseases 0.000 description 1
• 201000011200 hepatorenal syndrome Diseases 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 101150113423 hisD gene Proteins 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 102000056298 human AHCY Human genes 0.000 description 1
• 102000043401 human ARSB Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 208000036796 hyperbilirubinemia Diseases 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 208000008245 hypermethioninemia Diseases 0.000 description 1
• 208000015210 hypertensive heart disease Diseases 0.000 description 1
• 208000008384 ileus Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000126 in silico method Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 208000027139 infectious colitis Diseases 0.000 description 1
• 201000007119 infective endocarditis Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000010039 intracellular degradation Effects 0.000 description 1
• 244000000056 intracellular parasite Species 0.000 description 1
• 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
• 230000007872 intrahepatic cholestasis Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 238000007852 inverse PCR Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000037427 ion transport Effects 0.000 description 1
• 230000002530 ischemic preconditioning effect Effects 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
• 150000002584 ketoses Chemical class 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 230000004130 lipolysis Effects 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 150000004668 long chain fatty acids Chemical class 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000006674 lysosomal degradation Effects 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 101710130522 mRNA export factor Proteins 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 210000005171 mammalian brain Anatomy 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 201000007261 marantic endocarditis Diseases 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 210000001704 mesoblast Anatomy 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000006609 metabolic stress Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 229960003248 mifepristone Drugs 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 208000012091 mucopolysaccharidosis type IVB Diseases 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• 239000006225 natural substrate Substances 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000018360 neuromuscular disease Diseases 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000000508 neurotrophic effect Effects 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 208000016135 nonbacterial thrombotic endocarditis Diseases 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 108010028584 nucleotidase Proteins 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 210000003463 organelle Anatomy 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 201000004228 ovarian endometrial cancer Diseases 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• 230000027758 ovulation cycle Effects 0.000 description 1
• KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 210000000277 pancreatic duct Anatomy 0.000 description 1
• 210000001819 pancreatic juice Anatomy 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000036281 parasite infection Effects 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 208000000689 peptic esophagitis Diseases 0.000 description 1
• 208000011906 peptic ulcer disease Diseases 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
• 108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
• 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
• DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 230000002186 photoactivation Effects 0.000 description 1
• 238000005375 photometry Methods 0.000 description 1
• 230000029553 photosynthesis Effects 0.000 description 1
• 238000010672 photosynthesis Methods 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 238000004262 preparative liquid chromatography Methods 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 210000004206 promonocyte Anatomy 0.000 description 1
• 230000001915 proofreading effect Effects 0.000 description 1
• 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 230000009993 protective function Effects 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 244000000040 protozoan parasite Species 0.000 description 1
• 210000000512 proximal kidney tubule Anatomy 0.000 description 1
• 201000003489 pulmonary alveolar proteinosis Diseases 0.000 description 1
• 201000002765 pyometritis Diseases 0.000 description 1
• 229960003581 pyridoxal Drugs 0.000 description 1
• 235000008164 pyridoxal Nutrition 0.000 description 1
• 239000011674 pyridoxal Substances 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000009103 reabsorption Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000029219 regulation of pH Effects 0.000 description 1
• 230000037425 regulation of transcription Effects 0.000 description 1
• 230000009712 regulation of translation Effects 0.000 description 1
• 230000009711 regulatory function Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 210000005084 renal tissue Anatomy 0.000 description 1
• 210000004994 reproductive system Anatomy 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 201000002220 retinal hemangioblastoma Diseases 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 208000004124 rheumatic heart disease Diseases 0.000 description 1
• 108010054748 ribonuclease k6 Proteins 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 230000000698 schizophrenic effect Effects 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 206010039722 scoliosis Diseases 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000005204 segregation Methods 0.000 description 1
• 238000010187 selection method Methods 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 210000001625 seminal vesicle Anatomy 0.000 description 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 230000012488 skeletal system development Effects 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 231100000527 sperm abnormality Toxicity 0.000 description 1
• 108010091193 spermatogenesis associated factor Proteins 0.000 description 1
• 229940063673 spermidine Drugs 0.000 description 1
• 229940063675 spermine Drugs 0.000 description 1
• 201000002471 spleen cancer Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000013179 statistical model Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000005845 steroid sulfates Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000002537 thrombolytic effect Effects 0.000 description 1
• 201000005990 thymic dysplasia Diseases 0.000 description 1
• 230000002992 thymic effect Effects 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 230000008280 toxic mechanism Effects 0.000 description 1
• 231100000563 toxic property Toxicity 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
• 230000005029 transcription elongation Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 238000011426 transformation method Methods 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 230000007723 transport mechanism Effects 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 101150081616 trpB gene Proteins 0.000 description 1
• 101150111232 trpB-1 gene Proteins 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 239000000717 tumor promoter Substances 0.000 description 1
• 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000009452 underexpressoin Effects 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 208000027185 varicose disease Diseases 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 201000011531 vascular cancer Diseases 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 206010055031 vascular neoplasm Diseases 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 201000009371 venous hemangioma Diseases 0.000 description 1
• 230000028973 vesicle-mediated transport Effects 0.000 description 1
• 201000010653 vesiculitis Diseases 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
• QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1